@article{article, title  = {{2020TiP SOGUG-NEOWIN: A phase II, open-label, multi-centre trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and FGFR gene alterations}},

 publisher = {{Elsevier BV}},

 url = {{http://dx.doi.org/10.1016/j.annonc.2024.08.2106 }},

 year = {{2024}},

 month = {{9}},

 author = {{Loriot Y and Necchi A and Hussain SA and De Velasco Oria GA}},

 doi = {{10.1016/j.annonc.2024.08.2106}},

 volume = {{35}},

 journal = {{Annals of Oncology}},

 pages = {{S1163-S1164}},

 note = {{Accessed on 2024/12/22}}}